ArticleVeterinary world2026
Associations of C-reactive protein and neutrophil-to-lymphocyte ratio with cardiac remodeling, pulmonary hypertension, and survival outcomes in dogs with myxomatous mitral valve disease.
Article in Veterinary world, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Myxomatous mitral valve disease (MMVD) is the most common cardiac disorder in dogs and is frequently associated with progressive cardiac remodeling and pulmonary hypertension (PH). Increasing evidence suggests that systemic inflammation contributes to disease progression; however, the clinical relevance of inflammatory biomarkers in relation to cardiac structural changes and outcomes remains incompletely understood. This study aimed to evaluate the associations between C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), cardiac remodeling indices, PH, and survival outcomes in dogs with MMVD. Materials and Methods: A retrospective cohort study was conducted using medical records of 94 client-owned dogs diagnosed with MMVD between 2023 and 2025. Dogs were classified according to the American College of Veterinary Internal Medicine (ACVIM) stages (B1-D). Echocardiographic parameters, including left atrial (LA) volume, LA/Ao ratio, and left ventricular internal diameter, were assessed alongside PH status determined by tricuspid regurgitation velocity. Hematologic parameters and serum CRP concentrations were analyzed. Correlation, regression, receiver operating characteristic (ROC), and survival analyses were performed to determine associations and prognostic value. Results: LA enlargement was observed in 84.0% of dogs and increased with disease severity. CRP and NLR showed weak but statistically significant positive correlations with indexed LA volume (CRP: r = 0.31, p < 0.01; NLR: r = 0.29, p < 0.05). Neither biomarker demonstrated a significant association with PH. Indexed LA volume, rather than inflammatory biomarkers, was more strongly associated with echocardiographic indicators of PH risk. CRP exhibited moderate diagnostic performance for PH (area under the curve = 0.7517, p < 0.001), whereas NLR showed poor discrimination. Survival analysis revealed that dogs with elevated CRP levels and concurrent PH had significantly reduced survival probabilities. Although NLR increased with disease progression, its prognostic utility remained limited. Conclusion: Systemic inflammatory biomarkers, particularly CRP, are modestly associated with cardiac remodeling and survival in dogs with MMVD but are not reliable predictors of PH. Echocardiographic indices, especially LA remodeling, remain superior indicators of disease severity and PH risk. While CRP may provide adjunctive prognostic value, its clinical application should be interpreted cautiously alongside established imaging parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.